CARMAT Is Participating In The 2014 French Touch Conference In New York

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Paris, June 26, 2014

CARMAT (FR0010907956, ALCAR), the designer and developer of the world's most advanced total artificial heart project, providing an alternative for people suffering from terminal heart failure, is taking part in the French Touch Conference, which is being held in New York on June 26 and 27, 2014 (French Touch Conference).

Organized with the support of La French Tech, France Digitale and the Innovation Touch Association, the French Touch Conference brings together prominent French entrepreneurs and senior figures from every field of innovation, along with their American counterparts. Mrs Axelle Lemaire, Secretary of State for Digital Affairs, and Mrs Fleur Pellerin, Minister of State for Foreign Trade, the Promotion of Tourism and French Nationals Abroad, are also attending the event.

CARMAT's CEO Marcello Conviti is taking part in a debate on technologies in the health sector, entitled "A Different Kind of Tech - Health & Tech", on June 27.

"We are honored to have been invited to participate in 'La French Touch Conference'. This event will provide us with an opportunity to share our experience of a bold and unique French project in the medical technology sector with American entrepreneurs and investors", says Marcello Conviti, Chief Executive Officer of CARMAT.

About CARMAT: the world's most advanced total artificial heart project

The only credible response for all cases of end-stage heart failure, which is a real public health issue: CARMAT's aim is to be able to provide a response to a major public health issue associated with heart disease, the world's leading cause of death: chronic and acute heart failure. Indeed, this disease currently affects over 20 million patients in Europe and the United States. By pursuing the development of its total artificial heart, CARMAT intends to overcome the well-known shortfall in heart transplants for the tens of thousands of people suffering from heart failure.

The result of combining two types of unique expertise: the medical expertise of Professor Carpentier, known throughout the world for inventing Carpentier-Edwards® heart valves, which are the most used in the world, and the technological expertise of Airbus Group, world aerospace leader.

Imitating the natural heart: given its size, the choice of structural materials and its innovative physiological functions, CARMAT's total artificial heart could, assuming upcoming clinical trials are successful, potentially benefit the lives of tens of thousands of patients a year whilst ensuring there is no risk of rejection and providing them with an unparalleled quality of life.

A project leader acknowledged at a European level: with the backing of the European Commission, CARMAT has been granted the largest subsidy ever given to an SME by Bpifrance; a total of €33 million.

Strongly committed, prestigious founders and shareholders: Truffle Capital, a leading European venture capital firm, Airbus Group, the Fondation Alain Carpentier, the Centre Chirurgical Marie Lannelongue and the thousands of institutional and individual shareholders who have placed their trust in CARMAT.

For more information: www.carmatsa.com

Help employers find you! Check out all the jobs and post your resume.

Back to news